Measurable (or minimal) residual disease (MRD) is the presence of residual cancer cells that remain in the body during or after treatment. Tailoring treatment plans based on MRD may further improve risk stratification and optimize disease outcomes in several hematologic malignancies. However, the application of MRD testing for prognosis and treatment selection in routine practice needs more supporting data from large studies, and questions about its current and future role abound. The goal of the proposed CME-approved visiting faculty meeting series (N=10) to be held at community cancer centers and academic institutions throughout the United States is to provide the multidisciplinary team with expert perspectives and guidance on the clinical utility of MRD in the contemporary management of hematologic malignancies as well as the latest advances in testing methodologies. The activity will begin with the definition of MRD and its implications for prognosis and treatment selection, followed by a discussion of the advantages and limitations of current methods of detection. Faculty will then share consensus recommendations and best practices in MRD testing to set the stage for an exploration of the current and potential roles of MRD in clinical trials and routine practice in selected hematologic malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. At the close of the activity, learners will be given the opportunity to present questions to the faculty and gain expert perspectives on challenges related to the application of MRD in clinical trials and real-world settings. Maximizing the Reach and Distribution of the Educational Content Four weeks following activity completion, the activity chairperson will send a fully referenced Clinical Pearls learning retention email to the learners. The purpose of this communication is to: Reinforce the key learning takeaways of the activity Provide learners with an opportunity for further Q&As with the expert faculty Strengthen the dialogue in the treating community regarding patient care best practices, clinical trial enrollment, and other important topics To reinforce knowledge retention and expand the reach and distribution of the educational content to the broader health care provider audience, the activity slide set will be made accessible via the i3 Health website and mobile app.
- Provider:i3 Health
- Activity Link: https://www.i3health.com/course-information/enhancing-mrd-testing-in-hematologic-malignancies-when-negativity-is-a-positive-thing
- Start Date: 2024-02-20 06:00:00
- End Date: 2024-02-20 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Sanofi S.A. - Amount: 95000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology